Skip to main content
Reproductive Medicine and Biology logoLink to Reproductive Medicine and Biology
. 2025 Oct 21;24(1):e12686. doi: 10.1002/rmb2.12686

The Effect of Intrauterine Autologous Peripheral Blood Mononuclear Cells (PBMCs) Administration in Modulating the Immunologic Profile Aberrations in Repeated Implantation Failure (RIF) Women

Samaneh Abdolmohammadi‐Vahid 1, Mohammad Sadegh Soltani‐Zangbar 1, Ali Aghebati‐Maleki 1,2, Narges Nouri 1, Hamid Ahmadi 3, Shahla Danaii 1,4, Leili Aghebati‐Maleki 1,5,✉
PMCID: PMC12538644  PMID: 41127207

ABSTRACT

Purpose

Considering the immune‐related etiology of RIF, administration of an immunomodulatory approach such as autologous PBMCs seems to be helpful in modifying the dysregulated immune responses.

Methods

100 RIF women were divided into the PBMC receiving and the control group. Blood sampling was conducted 48 h before and 2 weeks after PBMC administration. The frequency of Th17, Treg, and NK cells, the expression level of related transcription factors and miRNAs, and the concentration of inflammatory and anti‐inflammatory cytokines were evaluated pre‐ and post‐treatment. Pregnancy outcome including pregnancy, live birth, and miscarriage rates were also evaluated.

Results

PBMC therapy significantly elevated the frequency of Th17 and NK cells (p = 0.0035 and 0.0013, respectively) and the expression of RORγt (p < 0.0001), in comparison with pre‐treatment, while the frequency of Treg cells (p = 0.0063) and the expression of FoxP3 and PTEN were decreased post treatment. The serum concentration of IL‐1β, IL‐17, and TNF‐α was increased, while IL‐10 and TGF‐β were reduced post‐treatment when compared to pre‐treatment. Pregnancy and live birth rates were significantly higher in the PBMC‐treated group in comparison with routine treatment.

Conclusion

Intrauterine administration of autologous PBMCs may be helpful in treating RIF patients, especially those with decreased inflammatory cells and mediators in the implantation process.

Keywords: implantation, PBMC, RIF, Th17, Treg


The experiment procedure of the study.

graphic file with name RMB2-24-e12686-g003.jpg

1. Introduction

Embryo implantation is the early stage of pregnancy in which the blastocyst attachment to the endometrial epithelium occurs in a coordinated event to support embryo growth [1]. A typical and healthy endometrium and bidirectional signaling between the endometrial epithelium and embryo are essential for a successful implantation [2]. Failure in implantation, which leads to embryo loss, makes the implantation process a critical limiting factor in the establishment of a successful pregnancy [3]. In vitro fertilization (IVF) is among the assisted reproductive technologies (ART) for improving fertility problems such as implantation failure [2, 4]. Although there has not been an agreement upon the definition of the condition known as recurrent implantation failure (RIF), failure in implantation and achieving pregnancy after transferring at least three good quality embryos in the IVF procedure is called RIF [1].

Solid evidence exists about the role of immune system imbalance in implantation failure [1, 5, 6]. Failure in maternal immunotolerance toward the embryo or fetus would cause pregnancy wastage. Regulatory mechanisms against the inflammatory cells and mediators are essential in the maintenance of a pregnancy [7]. On the other hand, an inflammatory microenvironment is required for uterus preparation in the early implantation stage [8]. Therefore, a delicate balance between T cell subsets is essential in the process of normal implantation and pregnancy, including a shift toward T helper 1 (Th1) cells and cytokines like interferon‐ɣ (IFNɣ) at the early stage of implantation and a shift toward Th2 cells and cytokines such as interleukin‐4 (IL‐4) and IL‐10 after implantation [9].

On the other hand, regulatory T cells (Treg) are the central mediator of tolerance in the feto‐maternal crosstalk and are involved in the implantation process and embryo development [10]. The involvement of Th17 inflammatory cells in human reproduction was indicated in the studies, which demonstrated that the increased frequency of these cells and associated cytokines, including IL‐17, was associated with a greater risk of pregnancy wastage [10, 11]. The ratio of Th17/Treg cells is among the predictors of the risk of pregnancy wastage; in addition to the Th1/Th2 ratio, failure in achieving the proper Th1/Th2 and Th17/Treg ratios is associated with reproductive failures such as RIF [12, 13]. Uterine natural killer (uNK) cells are the predominant population of the placenta in the early stage of pregnancy, which also play a crucial role in trophoblast invasion [14]. Data are accumulating that supports the role of immunologic dysregulation in the pathogenesis of implantation failure and pregnancy wastage [9, 11].

A group of endogenous short non‐coding RNAs, known as miRNAs, is the primary regulator of gene expression and various biological pathways, including hematopoiesis, inflammation, and the function of different immune cells by post‐transcriptional regulation of associated messenger RNAs (mRNAs) [15]. According to the literature, dysregulation of miRNA expression is involved in various pathologies, such as immune system‐related disorders [16]. In addition, miRNAs can regulate immune cell proliferation and function. For instance, Treg cell differentiation and function are controlled by mir‐155 by targeting forkhead box P3 (FoxP3), the main transcription factor of Treg. Decreased expression of this miRNA can affect the frequency of Treg cells [17, 18]. Mir‐155 also targets phosphatase and tensin homolog (PTEN), a tumor suppressor gene and a protein/lipid phosphatase, which may be involved in mice's decidualization and trophoblastic cell invasion [19]. In addition to mir‐155, mir‐940, which is downregulated in RIF patients, can also impair the proliferation of trophoblast cells. The essential proteins, including nuclear factor kappa‐light‐chain‐enhancer of activated B cells (NF‐κB), Wnt/β‐catenin, and zinc finger protein 672 (ZNF24), are the proposed targets of mir‐940 [20]; nevertheless, it is postulated that mir‐940 impairs the proliferation of trophoblast cells and promotes pregnancy wastage by targeting ZNF24 [21]. Dickkopf WNT Signaling Pathway Inhibitor 1 (DKK1) is also targeted by mir‐940 and mir‐144, downregulated in RIF women [22]. DKK1 can affect the implantation process by regulating embryo attachment [23]. On the other hand, cyclooxygenase‐2 (Cox‐2), as a target of mir‐144‐3p, is negatively regulated by this miRNA, as well as several inflammatory mediators, including IL‐1β, IL‐6, and tumor necrosis factor‐alpha (TNF‐α) [24].

The transforming growth factor‐beta (TGF‐β) pathway is essential for Treg cells' differentiation and function, modulated by proapoptotic gene activity, called BCL2L11/Bim [25]. Bim is the target gene of mir‐10a, and mir‐10a modulates cell apoptosis by downregulating the proapoptotic protein Bim [26]. Therefore, mir‐10a is the other regulator of Treg cells. A substitution polymorphism in miR‐10a may lead to the attenuated sensibility of cells to progesterone and pregnancy wastage. Target analysis of mir‐20b‐5p, a member of the mir‐106a‐363 cluster, indicated that upregulation of this miRNA could downregulate the expression of PTEN and Bim [27]. Mir‐718 is an anti‐inflammatory miRNA that targets Interleukin‐1 receptor‐associated kinase 1 (IRAK1) and subsequently negatively regulates NF‐κB activation, a transcription regulator of inflammatory cytokines. A systemic analysis of the miRNA profile of RIF women indicated that the expression of mir‐718 is downregulated in RIF women [23].

Given all the above, there is accumulating data indicating the role of immune cells and related miRNA in the pathogenesis of immune‐related reproductive disorders; therefore, an immunomodulatory approach is required for modifying the dysregulated immune responses through the implantation process [12]. Indeed, modulation of the maternal immune system in the case of immunologic abnormalities by immunologic approaches may help achieve or maintain the pregnancy and successful outcomes. Intrauterine peripheral blood mononuclear cells (PBMCs) therapy for reproductive failures is among these approaches [28]. Administration of PBMCs, containing T and B lymphocytes and monocytes, is capable of improving the implantation rate in RIF patients and positively affecting the blastocyte invasion to endometrium by upregulation of matrix metalloproteinase‐2 (MMP‐2) and MMP‐9 expression [29]. In addition, immunologic tolerance toward the embryo is improved following the intrauterine PBMCs administration [30], and PBMCs regulate the secretion of inflammatory cytokines such as IL‐1β and TNF‐α [31].

The current study aims to investigate the effect of intrauterine PBMCs administration on modulating RIF patients' immunologic abnormalities. To our knowledge, this is the first study in which the effect of intrauterine administration of autologous PBMCs was investigated on immunologic cells such as Th17, Treg, and NK cells, related cytokines, transcription factors, and miRNAs in humans, pre‐ and post‐treatment.

2. Material and Methods

2.1. Study Design and Subjects' Selection

Initially, one hundred RIF women were enrolled in the study. The participants were divided into two groups: 50 RIF patients who received intrauterine injections of human chorionic gonadotrophin (hCG)‐activated autologous PBMCs, 2 days before embryo transfer and 50 RIF patients who received routine treatment for RIF patients before ET. The immunologic parameters have been evaluated before (G2) and after (G4) PBMCs therapy and compared with the results of immunologic evaluations of women before (G1) and after (G3) routine treatment.

All subjects were under the following inclusion criteria: age between 20 and 45, three or more previous failures of in vitro fertilization‐ embryo transfer (IVF‐ET) therapy, and regular menstrual cycles. In the case of ovulatory disorder, anomalies, chromosomal aberrations, malignancies, diabetes, hypertension, infection, and other underlying diseases or receiving steroids or immunosuppressive drugs, the patients were excluded from the study. In addition, a semen analysis and DNA fragmentation test were performed for the partners of patients to select the patients with partners with typical test results. Demographic data of subjects is summarized in Table 1.

TABLE 1.

Clinical findings of the RIF patients.

Variable PBMCs receiving group mean ± SD (N = 50) Control group mean ± SD (N = 50) p
Maternal age (years, range) 32.89 ± 3.31 (23–42) 33.46 ± 3.44 (25–43) NS
Body mass index (kg/m2) 26.54 ± 2.68 27.73 ± 3.11 NS
Duration of infertility (years, range) 8.68 (4–18) 9.12 (3–20) NS
Number of transferred embryos 2.7 ± 1.32 2.93 ± 1.4 NS
No. of smoking patient 2 0 NS
No. of smoking partners 19 23 NS
No. of previous ET attempts 4.1 ± 2.03 4.4 ± 2.41 NS
No. of fresh cycles ET 22 21 NS
Abnormal karyotype 0 0 NS
Male infertility 0 0 NS
FSH (mIU/l) 6.71 ± 2.63 7.11 ± 2.94 NS
LH (mIL/l) 4.49 ± 1.8 4.56 ± 1.54 NS
E2 (pg/ml) 36.16 ± 14.31 35.21 ± 13.86 NS
PRL (ng/ml) 14.02 ± 5.12 12.35 ± 5.88 NS
Anti‐TPO 0 0 NS
Anti‐TG 0 0 NS
APA 0 0 NS
ACA 0 0 NS
ANA 0 0 NS
Anti‐ds DNA 0 0 NS
Pregnancy rate 23 (46%) 12 (24%) 0.035
Misscarriage rate Total From pregnant cases Total From pregnant cases Total From pregnant cases
6/50 (12%) 6/23 (26%) 5/50 (10%) 5/12 (41.66%) NS 0.18
Live birth rate 17/50 (34%) 17/23 (73.91%) 7/50 (14%) 7/12 (58.33%) 0.034 NS

Abbreviations: ACA, anti‐cardiolipin antibody; ANA, anti‐nuclear antibody; Anti‐ds DNA, anti‐double strand DNA; Anti‐TG, anti‐thyroglobulin; Anti‐TPO, anti‐thyroid peroxidase; APA, anti‐phospholipid antibody; BMI, body mass index; E2, estradiol 2; FSH, follicle stimulating hormone; HDL, high‐density lipoprotein; LDL, low‐density lipoprotein; LH, luteinizing hormone; PRL, prolactin.

Written informed consent was obtained from all the participants, and the study protocol was approved by the Research Ethics Committee of Tabriz University of Medical Sciences (IR. IR.NIMAD.REC.1400.4002376).

The first blood sampling was conducted 48 h before PBMC administration. The second was done 2 weeks after PBMC administration in both PBMC receiving and control groups to evaluate and compare the immunologic parameters pre‐ and post‐treatment.

2.2. PBMC Isolation and Injection

For PBMCs isolation, 20 mL of peripheral blood of each participant was collected in heparinized tubes at the time of ovulation induction. Gradient centrifugation using Ficoll‐Paque PLUS (GE Healthcare Bio‐Sciences AB) was utilized for PBMCs isolation. After centrifugation for 20 min at 450 g of the tube containing blood overlayed on Ficoll, PBMCs were collected from the interphase layer. The collected cells were washed twice with Roswell Park Memorial Institute 1640 (RPMI 1640) medium (Gibco BRL Co. Ltd., Grand Island, NY, USA), followed by suspension of 20–30 × 106 PBMCs in 8 mL RPMI 1640 supplemented with 10% heat‐inactivated FBS, and incubated in the presence of hCG (10 IU/mL daily) for 48 h at 37°C and 5% CO2 in 95% humidity incubator. After washing, 15 × 106 PBMCs were suspended in 500 μL PBS, followed by gentle administration of PBMCs to the uterine cavity using an embryo transfer catheter, which occurs 2 days before ET.

2.3. Evaluation of Treg, Th17, and NK Cells Frequency

Flow cytometry technique was used to analyze the frequency of Th17, Treg, and NK cells, prior to and post‐PBMC therapy. Initially, the cells (1 × 106) were stained with monoclonal antibodies against the surface markers, including fluorescein isothiocyanate (FITC)‐conjugated anti‐human CD4 (Clone SK3, 20 μL per test, BD Biosciences) for both Treg and Th17 cells. For evaluation of Treg cells frequency, phycoerythrin (PE)‐conjugated anti‐human CD25 (Clone 2A3 (RUO (GMP)), 20 μL per test, BD Biosciences) and allophycocyanin (APC)‐conjugated anti‐human CD127 (Clone HIL‐7R‐M21 (RUO), 5 μL per test, BD Biosciences) were also added to cells. Afterward, the cells were incubated at 4°C for 30 min, and then the cells were washed twice with phosphate‐buffered saline (PBS) (Sigma, Germany) and analyzed using FACS Calibur (BD Biosciences) flow cytometer. To evaluate Th17 cell frequency, the cells were stimulated with 10 ng/mL of PMA and 0.5 μM ionomycin (eBioscience) for 5 h at 37°C in a 5% CO2 incubator. In the next step, 0.5 μM of monensin (eBioscience) was added to cells to inhibit cytokine secretion and improve intracellular staining. After incubation time, the cells were collected by centrifugation at 300 g for 10 min. Afterward, the cells were prepared for intracellular staining using fixation and permeabilization buffer (eBioscience) and incubated at room temperature for 20 min. In the next step, PE‐conjugated anti‐human IL‐17 (Clone N49‐653 (RUO), 20 μL per test, BD Biosciences) was added and incubated for 30 min at room temperature. Afterward, the cells were washed and were ready for analysis.

Anti‐CD3 (Clone SK7 (also known as Leu‐4), 20 μL per test, BD Biosciences), Anti‐CD16 (Clone 3G8 (RUO) 20 μL per test, BD Biosciences), and anti‐CD56 (Clone NCAM16.2 (also known as NCAM 16), 5 μL per test, BD Biosciences) antibodies labeled with FITC, PE, and APC fluorochromes, respectively, were used for surface staining of NK cells. The FACS Calibur flow cytometer (BD Biosciences) and FlowJo software (Becton Dickinson, Mountain View, CA, USA) were used to analyze the population, and 10000 events were counted for each sample. Ultimately, the population of CD4+CD25+CD127−/low cells was determined as Treg cells, IL‐17+CD4+ cells were defined as Th17 cells, and CD3+CD16+CD56+ cells were determined as NK cells.

2.4. Evaluation of mRNA Expression Level of miRNAs, Transcription Factors, and PTEN

The gene expression of FoxP3 and RORγt, Treg, and Th17 associated transcription factors, alongside the gene expression of PTEN and mir‐10a, mir‐20b‐5p, mir‐144‐3p, mir‐155, mir‐718, and mir‐940, was evaluated among isolated PBMCs of RIF patients, before and after treatment, by using the real‐time polymerase chain reaction (PCR) method. TRIzol reagent (Sigma‐Aldrich, Steinheim, Germany) was utilized to extract the total RNA of isolated PBMCs, according to the manufacturer's recommendations. Extracted RNA was used as a template for cDNA synthesis with the help of the Revert Aid reverse transcriptase and random hexamer primer (Thermo Fisher Scientific).

SYBR Green method and the LightCycler 2.0 Real‐Time PCR System machine (Roche Applied Sciences, Mannheim, Germany) were utilized to evaluate gene expression using specific primers listed in Table 2. The thermocycling process was as follows: 95°C for 10 s (DNA denaturation) repeated for 40 cycles, 60°C for 10 s (annealing step), and 72°C for 20 s (extension step). Using the 2−ΔΔCt formula, the comparative Ct method was used to calculate the relative expression of target genes compared to the housekeeping controls, β‐actin and U6.

TABLE 2.

Primer pair sequences.

Gene Primer Sequence (5′ → 3′)
RORγT Forward GAGGAAGTGACTGGCTACCAGA
Reverse GCACAATCTGGTCATTCTGGCAG
FoxP3 Forward GGCACAATGTCTCCTCCAGAGA
Reverse CAGATGAAGCCTTGGTCAGTGC
PTEN Forward TGAGTTCCCTCAGCCGTTACCT
Reverse GAGGTTTCCTCTGGTCCTGGTA
miR‐10a Forward CCTGTAGATCCGAATTTG
Reverse GAACATGTCTGCGTATCTC
miR‐20b‐5p Forward TGCTCATAGTGCAGGTAG
Reverse GAACATGTCTGCGTATCTC
miR‐144‐3p Forward GGATATCATCATATACTGTA
Reverse GAACATGTCTGCGTATCTC
miR‐155 Forward TGCTAATCGTGATAGGGG
Reverse GAACATGTCTGCGTATCTC
miR‐718 Forward CTTCCGCCCCGCCGGGC
Reverse GAACATGTCTGCGTATCTC
miR‐940 Forward AAGGCAGGGCCCCCG
Reverse GAACATGTCTGCGTATCTC
β‐Actin Forward CACCATTGGCAATGAGCGGTTC
Reverse AGGTCTTTGCGGATGTCCACGT
U6 Forward CTCGCTTCGGCAGCACAT
Reverse TTTGCGTGTCATCCTTGCG

Abbreviations: FoxP3: forkhead box P3; miRs: micro RNAs; PTEN: phosphatase and TENsin homolog; RORγT: retinoic acid‐related orphan receptor gamma t.

2.5. Evaluation of Inflammatory and Anti‐Inflammatory Cytokines

The secretion levels of inflammatory (IL‐1β, TNF‐α, and IL‐17) and anti‐inflammatory (TGF‐β, IL‐10) cytokines (pg/mL) were measured in the serum of RIF patients, pre and post‐PBMC therapy, employing the ELISA kit (MyBioSource, San Diego, CA), based on the manufacturer's instructions. To enhance the accuracy of the test, all samples were analyzed in duplicate. A microplate reader measured the absorbance according to the standard curve.

2.6. Statistical Analysis

In the current study, the SPSS PC Statistics Software (version 19.0; SPSS Inc., Chicago, IL) and GraphPad Prism (version 7.00 for Windows; GraphPad Software, La Jolla, CA) were utilized to perform the statistical analysis and draw the graphs, respectively. Brown‐Forsythe ANOVA, followed by Dunnett's T3 multiple comparisons test, was employed to analyze the statistical differences in immunologic parameters between the groups (G1–G4). The data were indicated as the mean ± SD. p < 0.05 was represented as statistically significant. Pregnancy, live birth, and miscarriage rates were analyzed using Fisher's exact test among the study group.

3. Results

3.1. Circulating Treg, Th17, and NK Cells Frequency in RIF Patients, Pre‐ and Post‐Treatment

The results of our study indicated that there are no statistically significant differences in the frequency of Treg, Th17, and NK cells before and after routine treatment in the RIF group (G1 vs. G3) and among PBMCs receiving and routine treatment group before the treatment (G2 vs. G1) (Table 3). At the same time, PBMC therapy can significantly upregulate Th17 (p = 0.0035) and NK cells (p = 0.0013) frequency in these patients (G4), in comparison with pre‐treatment (G2). However, Treg cells were decreased as a result of PBMCs administration in RIF women (4.79% ± 2.26%) when compared with pre‐treatment (3.414% ± 1.755%) (p = 0.0063). Figure 1a,b illustrates the gating method and the abundance of Tregs, Th17 cells, and NK cells.

TABLE 3.

Summary of molecular and immunological characteristics of RIF patients before and after receiving PBMCs.

Target RIF patients before routine treatment (N = 50) mean ± SD (G1) RIF patients before PBMCs receiving (N = 50) mean ± SD (G2) RIF patients after routine treatment (N = 50) mean ± SD (G3) RIF patients after PBMCs receiving (N = 50) mean ± SD (G4) p value G1 vs. G2 p value G1 vs. G3 p value G1 vs. G4 p value G2 vs. G3 p value G2 vs. G4 p value G3 vs. G4
Flow cytometry
Th17 (%) 3.946 ± 1.781 3.88 ± 1.771 4 ± 1.949 5.222 ± 2.194 NS NS 0.0072 NS 0.0035 0.097
Treg (%) 4.692 ± 2.106 4.79 ± 2.26 4.874 ± 2.181 3.414 ± 1.755 NS NS 0.0131 NS 0.0063 0.0032
NK cells (%) 11.492 ± 3.953 11.502 ± 4.174 11.466 ± 4.054 14.516 ± 3.865 NS NS 0.0012 NS 0.0013 0.0011
Relative gene expression (fold change)
RORγT 1.000 ± 0.071 0.99 ± 0.294 1.071 ± 0.476 1.43 ± 0.722 NS NS < 0.0001 NS < 0.0001 0.0007
FoxP3 1.000 ± 0.097 1.024 ± 0.55 0.933 ± 0.313 0.72 ± 0.283 NS NS 0.0005 NS 0.0001 0.0139
PTEN 1.000 ± 0.084 0.983 ± 0.535 0.955 ± 0.381 0.697 ± 0.311 NS NS 0.0003 NS 0.0007 0.0029
miR‐10a 1.000 ± 0.062 1.019 ± 0.247 0.961 ± 0.408 0.676 ± 0.204 NS NS < 0.0001 NS < 0.0001 < 0.0001
miR‐20b 1.000 ± 0.076 1.021 ± 0.372 0.95 ± 0.26 0.713 ± 0.602 NS NS 0.0012 NS 0.0004 0.0109
miR‐144 1.000 ± 0.08 0.977 ± 0.217 1.044 ± 0.45 1.762 ± 1.623 NS NS < 0.0001 NS < 0.0001 0.0002
miR‐155 1.000 ± 0.077 1.017 ± 0.218 1.08 ± 0.519 1.663 ± 1.395 NS NS 0.0001 NS 0.0002 0.0009
miR‐718 1.000 ± 0.102 0.97 ± 0.453 1.037 ± 0.405 1.578 ± 1.284 NS NS 0.0004 NS 0.0002 0.0011
miR‐940 1.000 ± 0.094 0.989 ± 0.408 0.936 ± 0.306 2.146 ± 1.53 NS NS < 0.0001 NS < 0.0001 < 0.0001
ELISA (serum)
IL‐17 (pg/ml) 12.42 ± 6.719 13.33 ± 7.042 12.82 ± 6.134 17.47 ± 9.052 NS NS 0.0038 NS 0.0264 0.0093
IL‐1β (pg/ml) 6.346 ± 5.265 6.774 ± 5.396 6.896 ± 6.229 11.656 ± 9.394 NS NS 0.0007 NS 0.0023 0.0031
TNF‐α (pg/ml) 7.3 ± 6.602 6.942 ± 5.648 7.198 ± 6.093 11.222 ± 7.394 NS NS 0.0145 NS 0.0061 0.0114
IL‐10 (pg/ml) 5.162 ± 2.699 5.016 ± 2.516 5.388 ± 2.509 3.734 ± 1.789 NS NS 0.0175 NS 0.0410 0.0039
TGF‐β (pg/ml) 40.84 ± 20.975 42.02 ± 21.58 41 ± 24.108 28.76 ± 15.594 NS NS 0.0212 NS 0.0090 0.0190

Note: Data are presented as mean ± standard deviation. p < 0.05 is considered as significant.

Abbreviations: FoxP3, Forkhead box P3; ILs, Interleukins; miRs, micro RNAs; NK cells, natural killer cells; PTEN, phosphatase and TENsin homolog; RIF, repeated implantation failure; RORγT, retinoic acid‐related orphan receptor gamma t; TGF‐β, transforming growth factor beta; Th17, T helper 17 lymphocytes; TNF‐α, tumor necrosis factor alpha; Treg, regulatory T lymphocytes.

FIGURE 1.

FIGURE 1

Treg, Th17, and NK cell frequency in RIF patients pre‐ and post‐PBMC therapy. Panel (a, b) illustrates the gating strategy and the abundance of Tregs, Th17 cells, and NK cells. (c) PBMC therapy can significantly upregulate Th17 (p = 0.0035) and NK cells (p = 0.0013) frequency in RIF patients, compared with pre‐treatment. In contrast, when compared with pre‐treatment, Treg cells were decreased due to PBMCs administration in RIF women (p = 0.0063). PBMCs administration also significantly elevated the frequency of Th17 (p = 0.097) and NK cells (p = 0.0011) compared with routine treatment. In addition, the frequency of Treg cells was also significantly affected by PBMCs therapy, as it significantly decreased in PBMC‐receiving RIF patients compared to the routine treatment group (p = 0.0032). A difference was considered significant when p < 0.05 (PBMC‐receiving RIF patients; n = 50, Control group; n = 50).

The results also showed significant differences in the frequency of immune cells after routine treatment protocol for RIF women and intrauterine PBMC therapy. PBMCs administration was able to significantly elevate the frequency of NK cells (p = 0.0011) when compared with routine treatment (G3) (Figure 1c). Although the population of Th17 cells was elevated by PBMC therapy in comparison with the routine treatment group, this increase was not significant. In addition, the frequency of Treg cells was also significantly affected by PBMCs therapy (G4), as it was significantly decreased (p = 0.0032) in PBMC‐receiving RIF patients when compared to the routine treatment group (G3) (Figure 1c). The results are presented in detail in Table 3.

3.2. Transcription Level of miRNAs, Transcription Factors, and PTEN in RIF Patients, Pre‐ and Post‐Treatment

The transcription level of Treg and Th17‐related transcription factors, FoxP3 and RORγt, was evaluated in PBMCs of RIF patients in G1–G4 groups. The results demonstrated that the expression level of RORγt was upregulated as a result of PBMC therapy in RIF patients (G4), compared with the pre‐treatment level (G2) (p < 0.0001) (Figure 2a). However, the routine treatment protocol could not significantly affect the transcription level of RORγt (G1 vs. G3). In addition, PBMC therapy was successful in increasing the mRNA expression level of RORγt, in comparison with the routine treatment protocol (G3 vs. G4) (p = 0.0007). Figure 2 illustrates RORγT and FoxP3 gene expression in PBMCs and routine treatment‐receiving groups before and after treatment.

FIGURE 2.

FIGURE 2

Expression level of RORɣt and FoxP3 in RIF patients, pre‐ and post‐PBMC therapy. (a) The expression level of RORɣt was upregulated following PBMC therapy in RIF patients, compared with the pre‐treatment level (p < 0.0001). In addition, PBMC therapy succeeded in increasing the mRNA expression level of RORɣt, compared with routine treatment protocol (p = 0.0007). (b) In the case of FoxP3, a noticeable decrease was observed after treatment with PBMCs, compared with pre‐treatment (p = 0.0001). Additionally, the downregulation of Foxp3 expression was higher in the PBMC‐receiving group compared with the routine treatment group (p = 0.0139). A difference was considered significant when p < 0.05 (PBMC‐receiving RIF patients; n = 50, Control group; n = 50).

Figure 3 illustrates PTEN gene expression in PBMCs and routine treatment–receiving groups before and after treatment. In the case of FoxP3 and PTEN, a noticeable decrease was observed after treatment with PBMC (G4), compared with pre‐treatment (G2) (p = 0.0001 and p = 0.0007, respectively). Additionally, the downregulation of Foxp3 and PTEN expression was higher in the G4 group, compared with G3 (p = 0.0139 and p = 0.0029, respectively) (Figures 2b and 3). There was no significant difference regarding the expression of RORγt, Foxp3, and PTEN between PBMCs–receiving and routine treatment groups before the treatment (G2 vs. G1) (Figures 2b and 3 and Table 3).

FIGURE 3.

FIGURE 3

Expression level of PTEN in RIF patients, pre‐ and post‐PBMC therapy. An apparent decrease was observed in PTEN mRNA expression after treatment with PBMCs, compared with pre‐treatment (p = 0.0007). Additionally, the downregulation of PTEN expression was higher in the PBMC‐receiving group than in the routine treatment group (p = 0.0029). A difference was considered significant when p < 0.05 (PBMC‐receiving RIF patients; n = 50, Control group; n = 50).

Figure 4 illustrates the expression of different miRNAs in PBMCs and routine treatment‐receiving groups before and after treatment. As a result of PBMC therapy in RIF patients, the expression of mir‐10a and mir‐20b was downregulated in the G4 group, compared with the G2 group (p < 0.0001 and p = 0.0004, respectively) (Figure 4a,c). In contrast, PBMC therapy upregulates the expression of mir‐144, mir‐155, mir‐718, and mir‐940 post‐treatment (p < 0.0001, 0.0002, 0.0002, and < 0.0001, respectively) (Figure 4b,d–f). However, the routine treatment protocol could not significantly increase or decrease the expression of these miRNAs (G1 vs. G3).

FIGURE 4.

FIGURE 4

Expression level of miRNAs in RIF patients, pre‐and post‐PBMC therapy. (a, c) As a result of PBMC therapy in RIF patients, the expression of mir‐10a and mir‐20b was downregulated in the PBMC receiving group, compared with the routine treatment group (p < 0.0001 and p = 0.0004, respectively). In contrast, PBMC therapy upregulates the expression of mir‐144 (d), mir‐155 (b), mir‐718 (e), and mir‐940 (f) post‐treatment (p < 0.0001, 0.0002, 0.0002, and < 0.0001, respectively). However, the routine treatment protocol could not significantly increase or decrease the expression of these miRNAs. In a comparison of the PBMC receiving group and routine treatment group, the observed decrease in mir‐10a and mir‐20b expression by PBMC therapy was more powerful than routine treatment protocol (p < 0.0001 and 0.0109, respectively), as the same was observed in downregulation of mir‐144, mir‐155, mir‐718 and mir‐940 (p = 0.0002, 0.0009, 0.0011 and < 0.0001, respectively). A difference was considered significant when p < 0.05 (PBMC‐receiving RIF patients; n = 50, Control group; n = 50).

In comparison of the G3 and G4 groups, the observed decrease in mir‐10a and mir‐20b expression by PBMC therapy was more powerful than the routine treatment protocol (p < 0.0001 and 0.0109, respectively), as the same was observed in the downregulation of mir‐144, mir‐155, mir‐718, and mir‐940 (p = 0.0002, 0.0009, 0.0011, and < 0.0001, respectively) (Table 3 and Figure 4b,d–f). No significant difference was observed regarding the expression of the mentioned miRNAs between the PBMCs‐receiving and routine treatment groups before the treatment (G2 vs. G1) (Figure 4 and Table 3).

3.3. Concentration of Inflammatory and Anti‐Inflammatory Cytokines in RIF Patients, Pre‐ and Post‐Treatment

The concentration of inflammatory cytokines, including IL‐1β, IL‐17, and TNF‐α, was evaluated in the serum of RIF patients pre‐ and post‐PBMC therapy and routine treatment by ELISA. Figure 5 illustrates serum concentrations of inflammatory cytokines in PBMCs and routine treatment–receiving groups before and after treatment. Our results indicated that PBMC therapy was capable of upregulating the concentration of inflammatory cytokines post‐PBMC therapy when compared with the concentration of IL‐17 (Figure 5a), IL‐1β (Figure 5b), and TNF‐α (Figure 5c) before the treatment (G2 vs. G4) (p = 0.0023, 0.0264, and 0.0061, respectively). In comparing the G3 and G4 groups, the concentration of the abovementioned cytokines was also significantly higher in the G4 group (p = 0.0031, 0.0093, and 0.0114), as shown in Figure 5 and Table 3. However, no significant difference was observed regarding the concentration of these inflammatory cytokines between PBMCs–receiving and routine treatment groups before the treatment (G2 vs. G1) (Figure 5 and Table 3).

FIGURE 5.

FIGURE 5

Concentration of inflammatory cytokines in RIF patients, pre‐ and post‐PBMC therapy. PBMC therapy could upregulate the concentration of inflammatory cytokines post‐PBMC therapy compared with the concentration of IL‐17 (a), IL‐1β (b), and TNF‐α (c) before the treatment (p = 0.0023, 0.0264, and 0.0061, respectively). Compared to PBMC therapy and routine treatment protocol, the concentration of abovementioned cytokines was also significantly higher in the PBMC therapy group (p = 0.0031, 0.0093, and 0.0114). A difference was considered significant when p < 0.05 (PBMC‐receiving RIF patients; n = 50, Control group; n = 50).

Figure 6 illustrates serum concentrations of anti‐inflammatory cytokines in PBMCs and routine treatment‐receiving groups before and after treatment. In the case of anti‐inflammatory cytokines, including IL‐10 (Figure 6a) and TGF‐β (Figure 6b), intrauterine PBMC administration decreased the concentration of these cytokines post‐treatment (G4) when compared to pre‐treatment (p = 0.0410 and 0.0090, respectively) in RIF patients; however, the routine treatment protocol did not decrease the secretion of IL‐10 and TGF‐β (G1 vs. G3). As shown in Figure 6, PBMC therapy was more potent in downregulating the production of IL‐10 and TGF‐β in comparison with routine treatment (G3 vs. G4) (p = 0.0039 and 0.0190, respectively) (Table 3). There was no significant difference regarding the concentration of these anti‐inflammatory cytokines between PBMCs‐receiving and routine treatment groups before the treatment (G2 vs. G1) (Figure 6 and Table 3).

FIGURE 6.

FIGURE 6

Concentration of anti‐inflammatory cytokines in RIF patients, pre‐ and post‐PBMC therapy. Intrauterine PBMC administration decreased the concentration of IL‐10 (a) and TGF‐β (b) cytokines post‐treatment compared to pre‐treatment (p = 0.0410 and 0.0090, respectively) in RIF patients. However, the routine treatment protocol did not decrease the secretion of IL‐10 and TGF‐β. PBMC therapy was also more potent in downregulating the production of IL‐10 and TGF‐β compared to routine treatment (p = 0.0039 and 0.0190, respectively). A difference was considered significant when p < 0.05 (PBMC‐receiving RIF patients; n = 50, Control group; n = 50).

3.4. Pregnancy, Live Birth and Miscarriage Rate in PBMC Treated and Routine Treatment RIF Patients

The rate of pregnancy was significantly higher in PBMC‐treated RIF women (46%) when compared to that of the routine treatment group (24%, p = 0.035). PBMC therapy was capable of increasing the live birth rate in comparison with routine treatment protocols [17/50 (34%) vs. 7/50 (14%), p = 0.034], while there was no statistically significant difference among the groups regarding miscarriage rate in spite of the higher rate of miscarriage in the routine treatment group (Table 1).

4. Discussion

There is solid evidence about the role of immunologic aberrations in the pathogenesis of implantation failure; therefore, there is a growing need for immunomodulatory approaches in the case of immunologic disturbances' involvement in the pathogenesis of reproductive failure. Our study aimed to investigate the effect of intrauterine hCG‐activated PBMCs injection in improving immunologic abnormalities presented in RIF patients, with immunologic abnormalities including decreased peripheral Th17 and NK cell numbers and concentration of inflammatory cytokines (IL‐17, IL‐1β, and TNF‐α) and increased Treg frequency and concentration of IL‐10 and TGF‐β. According to our results, PBMC therapy, as a helpful approach, can increase the frequency of inflammatory Th17 cells alongside NK cells in peripheral blood. At the same time, this treatment protocol could downregulate the frequency of Treg cells in these patients. In line with these results, the gene expression level of related transcription factors was also affected by PBMC therapy in peripheral blood, as the expression level of RORγt, a Th17‐associated transcription factor, was increased post‐treatment.

In contrast, mRNA expression of FoxP3, a transcription factor of Treg cells, and PTEN expression was decreased. RIF patients who received the routine treatment protocol did not indicate any significant difference in the immunologic parameters before and after treatment. In addition, a comparison of the treatment results of PBMC receiving and routine treatment groups also demonstrated that PBMC therapy is more potent in the modulation of immunologic aberration in RIF patients.

At the same time, evaluation of inflammatory cytokines in peripheral blood, including IL‐17, IL‐1β, and TNF‐α, in the serum of RIF women in both groups demonstrated that the concentration of these cytokines is increased following treatment with PBMCs. In contrast, the concentration of regulatory cytokines, IL‐10 and TGF‐β, was downregulated post‐treatment. In summary, PBMC therapy shifted toward inflammatory responses, which are essential in implantation.

Additionally, evaluation of pregnancy outcome among the groups of the current study demonstrated that PBMC therapy was capable of improving the pregnancy and live birth rate and reducing the miscarriage rate among RIF women when compared with the RIF women who received routine treatment.

Alteration of the immune system to accept the semi‐allogenic developing embryo and fetus occurs at both local (uterine and decidua) and systemic (peripheral blood) levels, under the influence of steroid hormones. Since the immune cells in the decidua are directly in contact with the developing fetus and under the influence of an increased concentration of steroid hormone in female reproductive tracts, they undergo drastic changes in terms of number and functionality. Usually (but not always) these alterations are reflected in systemic immune alterations. In terms of reproduction and pregnancy, the immune system can be investigated at both local (uterus and decidua) and systemic (peripheral) levels. Investigating the immune system in human decidua is highly restricted because of ethical issues. The evaluation of immune cells and their functions in peripheral blood is a proper alternative [32].

To our knowledge, this is the first study in which the effect of intrauterine administration of autologous PBMCs was investigated on immunologic cells such as Th17, Treg, and NK cells, cytokines, transcription factors, and related miRNAs in humans, pre‐ and post‐treatment.

Many studies evaluated the effect of intrauterine administration of PBMCs, whether activated with hormones or not, on the implantation, pregnancy, live birth, and miscarriage rate in RIF women without considering the alteration of immunologic parameters. A study by Madkour et al. demonstrated that endometrium immuno‐modulation before fresh embryo transfer, by intrauterine insemination of cultured PBMCs, could significantly increase the implantation and clinical pregnancy rate compared to the control group [33]. The same positive effect of PBMC administration for patients with ≥ 3 RIF was observed in the study of Nobijari et al. [34] and Okitsu et al. [35], in which the clinical pregnancy and implantation rate were significantly increased. Systematic reviews and meta‐analyses indicated the benefit of intrauterine PBMCs administration in improving implantation, clinical pregnancy, and live birth in RIF patients [36, 37, 38], in addition to decreasing the miscarriage rate [39]. The study of Pourmoghaddam et al. investigated the effect of intrauterine administration of autologous hCG‐activated PBMCs in the RIF women, considering the patients who had a low Th17, Treg frequency, and Th17/Treg ratio in comparison with the healthy control group before treatment. The results demonstrated that these RIF patients experienced a significantly higher pregnancy and live birth and lower miscarriage rate than the control group, which received PBS; however, the Th17 and Treg cell frequency was not evaluated after treatment. To assess the optimum incubation time for PBMC culture, the culture supernatant was evaluated for cytokine secretion of TNF‐α, IL‐1β, and IFN‐γ and 48 h of culture induced the highest amount of the inflammatory cytokines, in comparison with 2 and 24 h [30].

In the current study, alterations of miRNA expression were also investigated. The results demonstrated that the expression of mir‐10a and mir‐20b‐5p was downregulated post‐treatment. In contrast, the expression of mir‐144‐3p, mir‐155, mir‐718, and mir‐940 was increased following PBMC therapy. According to the literature, mir‐155 targets FoxP3 and PTEN and regulates the expression of PTEN in the HTR8/SVneo cell line as a first‐trimester human trophoblast cell line and, therefore, can regulate apoptosis by the AP‐1/NF‐κB pathway [40]. PTEN may also be involved in the apoptosis of luminal epithelial and decidual cells in mice's decidualization process and trophoblastic cell invasion [19]. The other proposed target for mir‐155 is membrane protein palmitoylated 5 (MPP5) or Stardust, a regulated protein during the menstrual cycle, and its secretion decreases from the proliferative to the late secretory phases [41]. The reduced expression of this protein in RIF patients is consistent with the increased expression of mir‐155 in RIF women [23]. Insulin‐like growth factor 2 (IGF2), a protein expressed in a high amount in the implantation process, is also downregulated by mir‐155 [42]. In addition to mir‐155, mir‐940, downregulated in RIF patients, can also target IGF2 [23]. Another study suggests that mir‐940 expression is significantly upregulated in the placental villi of women who experience miscarriages and can impair trophoblast cells' proliferation. NF‐κB, Wnt/β‐catenin, and ZNF24 are the proposed targets of mir‐940 [20]; however, it is postulated that mir‐940 impairs the proliferation of trophoblast cells and promotes pregnancy wastage by targeting ZNF24 [21]. Therefore, further study needs to be conducted to confirm the exact function of mir‐940. DKK1, a target of mir‐940 and mir‐144‐3p, affects the process of implantation by regulation of embryo attachment [23]. On the other hand, Cox‐2 is negatively regulated by mir‐144‐3p. Downregulation of mir‐144‐3p would lead to Cox‐2 upregulation in preeclamptic placental tissue [43]. Another relevant study also indicated that mir‐144‐3p can target several inflammatory mediators in addition to Cox‐2, including IL‐1β, IL‐6, and TNF‐α, which are involved in the pathogenesis of endometriosis [24]. Additionally, c‐fos, the transcriptional activator of COX2, is the other target of mir‐144, which plays a crucial role in the production of amnion prostaglandin E2 (PGE2) during pregnancy and labor [44] Mir‐718 targets IRAK1 and subsequently negatively regulates NF‐κB activation. On the other hand, PTEN is also targeted by mir‐718. PTEN is capable of controlling the PI3K/Akt pathway. PTEN degradation promotes the phosphorylation of Akt; subsequently, activated Akt suppresses the expression of inflammatory cytokines by NF‐κB [45]. A systemic analysis about the miRNA profile of RIF women indicated that the expression of mir‐718 is downregulated in RIF women [23]. It is suggested that mir‐20b‐5p also affects placental development through regulation of the expression of two proteins, Eph receptor B4 (EPHB4) and ephrin‐B2, which are responsible for trophoblast invasion and angiogenesis [46, 47].

Chen B.Sc. and colleagues' study investigated the differentially expressed miRNAs in RIF patients, which regulate the genes involved in RIF and endometrial receptivity. In line with our findings, the results of the abovementioned study demonstrated that mir‐20b‐5p was upregulated in RIF patients. At the same time, mir‐718, mir‐940, and mir‐144‐3p were downregulated, except mir‐155‐5p, which was upregulated in the Chen B.Sc. study, in contrast with our results [23].

There are controversies about the exact targets and function of miRNAs, from the immunologic point of view, in the process of implantation and pregnancy. The role of some miRNAs is almost confirmed; however, there are disagreements about the others. For example, it has been confirmed that mir‐155 regulates Treg cells' function. Downregulation of this miRNA in RIF patients would lead to overexpression of the targets, such as FoxP3, PTEN, and suppressor of cytokine signaling 1 (SOCS1), known as a negative regulator of cytokine signaling involved in Treg cell suppressor function [11]. Overexpression of FoxP3, PTEN, and probably SOCS1 in RIF patients is modulated by PBMC therapy, as the expression level of mir‐155 was increased and the expression of FoxP3 and PTEN decreased post‐treatment. In addition to mir‐155, mir‐144‐3p, mir‐718, and mir‐940 were also confirmed to be downregulated in RIF patients in relevant studies [23]. However, PBMC therapy was able to elevate the expression level of these miRNAs in our study. According to our data, it is postulated that these four miRNAs are involved in the process of implantation, decidualization, or inflammation and are capable of improving the suitable microenvironment for successful implantation. However, there is some opposite evidence about the anti‐inflammatory effect of mir‐780 and mir‐940.

5. Conclusion

Considering the immunomodulatory power of intrauterine PBMC administration for the immunologic aberrations of RIF patients and its positive effects in improving the pregnancy outcome, PBMC therapy may be helpful in treating these patients, especially those with decreased inflammatory cells and mediators in the implantation process. Consistent with this, our data also support the benefit of PBMC administration for regulating the miRNAs involved in the development of reproductive failures, where they mediate the regulation of the immune balance of feto‐maternal crosstalk.

Conflicts of Interest

The authors declare no conflicts of interest.

Acknowledgments

This study was supported by the Immunology Research Center at Tabriz University of Medical Sciences, Iran.

Abdolmohammadi‐Vahid S., Soltani‐Zangbar M. S., Aghebati‐Maleki A., et al., “The Effect of Intrauterine Autologous Peripheral Blood Mononuclear Cells (PBMCs) Administration in Modulating the Immunologic Profile Aberrations in Repeated Implantation Failure (RIF) Women,” Reproductive Medicine and Biology 24, no. 1 (2025): e12686, 10.1002/rmb2.12686.

Funding: Research reported in this publication was supported by Elite Researcher Grant Committee under award number (Grant No. 4002376) from the National Institute for Medical Research Development (NIMAD), Tehran, Iran.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

References

  • 1. Bashiri A., Halper K. I., and Orvieto R., “Recurrent Implantation Failure‐Update Overview on Etiology, Diagnosis, Treatment and Future Directions,” Reproductive Biology and Endocrinology 16, no. 1 (2018): 1–18. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Coughlan C., Ledger W., Wang Q., et al., “Recurrent Implantation Failure: Definition and Management,” Reproductive Biomedicine Online 28, no. 1 (2014): 14–38. [DOI] [PubMed] [Google Scholar]
  • 3. Simon A. and Laufer N., “Assessment and Treatment of Repeated Implantation Failure (RIF),” Journal of Assisted Reproduction and Genetics 29, no. 11 (2012): 1227–1239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Mascarenhas M., Jeve Y., Polanski L., Sharpe A., and Yasmin E., “Management of Recurrent Implantation Failure: British Fertility Society Policy and Practice Guideline,” Human Fertility 25, no. 5 (2021): 813–837. [DOI] [PubMed] [Google Scholar]
  • 5. Kwak‐Kim J., Chung‐Bang H., Ng S., et al., “Increased T Helper 1 Cytokine Responses by Circulating T Cells Are Present in Women With Recurrent Pregnancy Losses and in Infertile Women With Multiple Implantation Failures After IVF,” Human Reproduction 18, no. 4 (2003): 767–773. [DOI] [PubMed] [Google Scholar]
  • 6. Sacks G., Yang Y., Gowen E., Smith S., Fay L., and Chapman M., “Detailed Analysis of Peripheral Blood Natural Killer Cells in Women With Repeated IVF Failure,” American Journal of Reproductive Immunology 67, no. 5 (2012): 434–442. [DOI] [PubMed] [Google Scholar]
  • 7. Yang F., Zheng Q., and Jin L., “Dynamic Function and Composition Changes of Immune Cells During Normal and Pathological Pregnancy at the Maternal‐Fetal Interface,” Frontiers in Immunology 10 (2019): 2317. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Dekel N., Gnainsky Y., Granot I., and Mor G., “Inflammation and Implantation,” American Journal of Reproductive Immunology 63, no. 1 (2010): 17–21. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Wang W., Sung N., Gilman‐Sachs A., and Kwak‐Kim J., “T Helper (Th) Cell Profiles in Pregnancy and Recurrent Pregnancy Losses: Th1/Th2/Th9/Th17/Th22/Tfh Cells,” Frontiers in Immunology 11 (2020): 2025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Lee S., Kim J., Hur S., et al., “An Imbalance in Interleukin‐17‐Producing T and Foxp3+ Regulatory T Cells in Women With Idiopathic Recurrent Pregnancy Loss,” Human Reproduction 26, no. 11 (2011): 2964–2971. [DOI] [PubMed] [Google Scholar]
  • 11. Ghaebi M., Abdolmohammadi‐Vahid S., Ahmadi M., et al., “T Cell Subsets in Peripheral Blood of Women With Recurrent Implantation Failure,” Journal of Reproductive Immunology 131 (2019): 21–29. [DOI] [PubMed] [Google Scholar]
  • 12. Parhizkar F., Motavalli‐Khiavi R., Aghebati‐Maleki L., et al., “The Impact of New Immunological Therapeutic Strategies on Recurrent Miscarriage and Recurrent Implantation Failure,” Immunology Letters 236 (2021): 20–30. [DOI] [PubMed] [Google Scholar]
  • 13. Ng S. C., Gilman‐Sachs A., Thaker P., Beaman K. D., Beer A. E., and Kwak‐Kim J., “Expression of Intracellular Th1 and Th2 Cytokines in Women With Recurrent Spontaneous Abortion, Implantation Failures After IVF/ET or Normal Pregnancy,” American Journal of Reproductive Immunology 48, no. 2 (2002): 77–86. [DOI] [PubMed] [Google Scholar]
  • 14. Jafarpour R., Pashangzadeh S., Mehdizadeh S., Bayatipoor H., Shojaei Z., and Motallebnezhad M., “Functional Significance of Lymphocytes in Pregnancy and Lymphocyte Immunotherapy in Infertility: A Comprehensive Review and Update,” International Immunopharmacology 87 (2020): 106776. [DOI] [PubMed] [Google Scholar]
  • 15. Sato F., Tsuchiya S., Meltzer S. J., and Shimizu K., “MicroRNAs and Epigenetics,” FEBS Journal 278, no. 10 (2011): 1598–1609. [DOI] [PubMed] [Google Scholar]
  • 16. Omar J., Moore C. S., Kennedy T. E., Antel J. P., Bar‐Or A., and Dhaunchak A. S., “MicroRNA Dysregulation in Multiple Sclerosis,” Frontiers in Genetics 3 (2013): 311. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. Zheng Y., Josefowicz S. Z., Kas A., Chu T.‐T., Gavin M. A., and Rudensky A. Y., “Genome‐Wide Analysis of Foxp3 Target Genes in Developing and Mature Regulatory T Cells,” Nature 445, no. 7130 (2007): 936–940. [DOI] [PubMed] [Google Scholar]
  • 18. Gavin M. A., Rasmussen J. P., Fontenot J. D., et al., “Foxp3‐Dependent Programme of Regulatory T‐Cell Differentiation,” Nature 445, no. 7129 (2007): 771–775. [DOI] [PubMed] [Google Scholar]
  • 19. Chen X.‐L., Ma H.‐L., Xie Y., Yang R., and Wei S.‐L., “Expression of Phosphatase and Tensin Homolog Deleted on Chromosome Ten in Mouse Endometrium and Its Effect During Blastocyst Implantation,” Acta Physiologica Sinica 60, no. 1 (2008): 119–124. [PubMed] [Google Scholar]
  • 20. Liu X., Ge X., Zhang Z., et al., “MicroRNA‐940 Promotes Tumor Cell Invasion and Metastasis by Downregulating ZNF24 in Gastric Cancer,” Oncotarget 6, no. 28 (2015): 25418–25428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Zhang W., Liu X., Yang Y., Ayi N., and Li L., “Highly Expressed microRNA‐940 Promotes Early Abortion by Regulating Placenta Implantation by Targeting ZNF672,” European Review for Medical and Pharmacological Sciences 23, no. 7 (2019): 2693–2700. [DOI] [PubMed] [Google Scholar]
  • 22. Wong N. and Wang X., “miRDB: An Online Resource for microRNA Target Prediction and Functional Annotations,” Nucleic Acids Research 43, no. D1 (2015): D146–D152. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Chen C. H., Lu F., Yang W. J., et al., “A Novel Platform for Discovery of Differentially Expressed microRNAs in Patients With Repeated Implantation Failure,” Fertility and Sterility 116, no. 1 (2021): 181–188. [DOI] [PubMed] [Google Scholar]
  • 24. Nothnick W. B., Swan K., Flyckt R., Falcone T., and Graham A., “Human Endometriotic Lesion Expression of the miR‐144‐3p/miR‐451a Cluster, Its Correlation With Markers of Cell Survival and Origin of Lesion Content,” Scientific Reports 9, no. 1 (2019): 1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Yamagiwa S., Gray J. D., Hashimoto S., and Horwitz D. A., “A Role for TGF‐β in the Generation and Expansion of CD4+ CD25+ Regulatory T Cells From Human Peripheral Blood,” Journal of Immunology 166, no. 12 (2001): 7282–7289. [DOI] [PubMed] [Google Scholar]
  • 26. Xiao G.‐Y., Cheng C.‐C., Chiang Y.‐S., Cheng W. T.‐K., Liu I., and Wu S.‐C., “Exosomal miR‐10a Derived From Amniotic Fluid Stem Cells Preserves Ovarian Follicles After Chemotherapy,” Scientific Reports 6, no. 1 (2016): 1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Drobna M., Szarzyńska B., Jaksik R., et al., “Hsa‐miR‐20b‐5p and Hsa‐miR‐363‐3p Affect Expression of PTEN and BIM Tumor Suppressor Genes and Modulate Survival of T‐ALL Cells In Vitro,” Cells 9, no. 5 (2020): 1137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28. Pourakbari R., Ahmadi H., Yousefi M., and Aghebati‐Maleki L., “Cell Therapy in Female Infertility‐Related Diseases: Emphasis on Recurrent Miscarriage and Repeated Implantation Failure,” Life Sciences 258 (2020): 118181. [DOI] [PubMed] [Google Scholar]
  • 29. Yoshioka S., Fujiwara H., Nakayama T., Kosaka K., Mori T., and Fujii S., “Intrauterine Administration of Autologous Peripheral Blood Mononuclear Cells Promotes Implantation Rates in Patients With Repeated Failure of IVF–Embryo Transfer,” Human Reproduction 21, no. 12 (2006): 3290–3294. [DOI] [PubMed] [Google Scholar]
  • 30. Pourmoghadam Z., Soltani‐Zangbar M. S., Sheikhansari G., et al., “Intrauterine Administration of Autologous hCG‐Activated Peripheral Blood Mononuclear Cells Improves Pregnancy Outcomes in Patients With Recurrent Implantation Failure; A Double‐Blind, Randomized Control Trial Study,” Journal of Reproductive Immunology 142 (2020): 103182. [DOI] [PubMed] [Google Scholar]
  • 31. Yakin K., Oktem O., and Urman B., “Intrauterine Administration of Peripheral Mononuclear Cells in Recurrent Implantation Failure: A Systematic Review and Meta‐Analysis,” Scientific Reports 9, no. 1 (2019): 1–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Hyde K. J. and Schust D. J., “Immunologic Challenges of Human Reproduction: An Evolving Story,” Fertility and Sterility 106, no. 3 (2016): 499–510. [DOI] [PubMed] [Google Scholar]
  • 33. Madkour A., Bouamoud N., Louanjli N., et al., “Intrauterine Insemination of Cultured Peripheral Blood Mononuclear Cells Prior to Embryo Transfer Improves Clinical Outcome for Patients With Repeated Implantation Failures,” Zygote 24, no. 1 (2016): 58–69. [DOI] [PubMed] [Google Scholar]
  • 34. Nobijari F. F., Arefi S. S., Moini A., et al., “Endometrium Immunomodulation by Intrauterine Insemination Administration of Treated Peripheral Blood Mononuclear Cell Prior Frozen/Thawed Embryos in Patients With Repeated Implantation Failure,” Zygote 27, no. 4 (2019): 214–218. [DOI] [PubMed] [Google Scholar]
  • 35. Okitsu O., Kiyokawa M., Oda T., Miyake K., Sato Y., and Fujiwara H., “Intrauterine Administration of Autologous Peripheral Blood Mononuclear Cells Increases Clinical Pregnancy Rates in Frozen/Thawed Embryo Transfer Cycles of Patients With Repeated Implantation Failure,” Journal of Reproductive Immunology 92, no. 1–2 (2011): 82–87. [DOI] [PubMed] [Google Scholar]
  • 36. Maleki‐Hajiagha A., Razavi M., Rezaeinejad M., et al., “Intrauterine Administration of Autologous Peripheral Blood Mononuclear Cells in Patients With Recurrent Implantation Failure: A Systematic Review and Meta‐Analysis,” Journal of Reproductive Immunology 131 (2019): 50–56. [DOI] [PubMed] [Google Scholar]
  • 37. Wu Y., Li L., Liu L., et al., “Autologous Peripheral Blood Mononuclear Cells Intrauterine Instillation to Improve Pregnancy Outcomes After Recurrent Implantation Failure: A Systematic Review and Meta‐Analysis,” Archives of Gynecology and Obstetrics 300, no. 5 (2019): 1445–1459. [DOI] [PubMed] [Google Scholar]
  • 38. Wang C., Guan D., Li R., Bing Z., Yang Y., and Yang K., “Comparative Efficacies of Different Immunotherapy Regimens in Recurrent Implantation Failure: A Systematic Review and Network Meta‐Analysis,” Journal of Reproductive Immunology 148 (2021): 103429. [DOI] [PubMed] [Google Scholar]
  • 39. Pourmoghadam Z., Abdolmohammadi‐Vahid S., Pashazadeh F., Ansari F., and Yousefi M., “Efficacy of Intrauterine Administration of Autologous Peripheral Blood Mononuclear Cells on the Pregnancy Outcomes in Patients With Recurrent Implantation Failure: A Systematic Review and Meta‐Analysis,” Journal of Reproductive Immunology 137 (2020): 103077. [DOI] [PubMed] [Google Scholar]
  • 40. Bidarimath M., Khalaj K., Wessels J. M., and Tayade C., “MicroRNAs, Immune Cells and Pregnancy,” Cellular & Molecular Immunology 11, no. 6 (2014): 538–547. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Whitby S., Salamonsen L. A., and Evans J., “The Endometrial Polarity Paradox: Differential Regulation of Polarity Within Secretory‐Phase Human Endometrium,” Endocrinology 159, no. 1 (2018): 506–518. [DOI] [PubMed] [Google Scholar]
  • 42. Singh M., Chaudhry P., and Asselin E., “Bridging Endometrial Receptivity and Implantation: Network of Hormones, Cytokines, and Growth Factors,” Journal of Endocrinology 210, no. 1 (2011): 5–14. [DOI] [PubMed] [Google Scholar]
  • 43. Hu S., Li J., Tong M., et al., “MicroRNA‐144‐3p May Participate in the Pathogenesis of Preeclampsia by Targeting Cox‐2,” Molecular Medicine Reports 19, no. 6 (2019): 4655–4662. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Li H., Zhou J., Wei X., et al., “miR‐144 and Targets, c‐Fos and Cyclooxygenase‐2 (COX2), Modulate Synthesis of PGE2 in the Amnion During Pregnancy and Labor,” Scientific Reports 6, no. 1 (2016): 1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Kalantari P., Harandi O. F., Agarwal S., et al., “miR‐718 Represses Proinflammatory Cytokine Production Through Targeting Phosphatase and Tensin Homolog (PTEN),” Journal of Biological Chemistry 292, no. 14 (2017): 5634–5644. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Wang W., Feng L., Zhang H., et al., “Preeclampsia Up‐Regulates Angiogenesis‐Associated microRNA (Ie., miR‐17, ‐20a, and ‐20b) That Target Ephrin‐B2 and EPHB4 in Human Placenta,” Journal of Clinical Endocrinology and Metabolism 97, no. 6 (2012): E1051–E1059. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Cai M., Kolluru G. K., and Ahmed A., “Small Molecule, Big Prospects: microRNA in Pregnancy and Its Complications,” Journal of Pregnancy 2017 (2017): 6972732. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.


Articles from Reproductive Medicine and Biology are provided here courtesy of John Wiley & Sons Australia, Ltd on behalf of Japan Society for Reproductive Medicine.

RESOURCES